Alterations in serum thrombotic biomarker in patients with acute myocardial infarction
Poster Mar 24, 2015
Abdullah S. Alhomida
Background: Acute myocardial infarction (AMI) is a critical condition with a high rate of mortality and morbidity. There is a need of developing technologies for novel biomarkers or signatures discovery towards point-of-care testing for the management of AMI. The plasminogen activator system is an important defense mechanism against intravascular thrombosis. Tissue plasminogen activator (TPA) is a protein involved in the breakdown of blood clots by catalyzing the conversion of plasminogen to plasmin, the major enzyme responsible for clot breakdown. In a clotting situation, TPA is released from the storage pools in the endothelium and initiates fibrin breakdown. Plasminogen activator inhibitor-1 (PAI-1) functions as a principal inhibitor of TPA and hence counteracts fibrinolysis, the physiological process that degrades blood clots. The overall fibrinolytic activity is mainly determined by the balance between TPA and PAI-1 levels.
Aims: We compared the serum levels of TPA and PAI-1 in AMI patients versus healthy controls as well as a group of patients with dyslipidemia and high blood pressure risk group).
Results: Our results showed significantly higher levels of both TPA (5.2 ± 0.22 versus 2.5 ± 0.13 ng/mL) and PAI-1 (16.3 ± 0.24 versus 10.1 ± 0.17 ng/mL) in the sera of AMI patients as compared to controls whereas the risk group showed only non-significant increases.
Conclusion: A combination of these biomarkers could serve as a useful biomarker tool to assess the prognosis of AMI. (This study was supported by National Plan for Science and Technology Program by King Saud University Project Number 08-BIO571-02).
The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that regulate the expression of phase I (cytochrome P450s), phase II metabolizing enzymes and transporter genes in response to xenobiotics, including prescription drugs.READ MORE
RNA interference (RNAi) using small interfering RNAs (siRNAs) is an important technology for down-regulation of gene expression and a powerful tool to study cellular processes and pathways. Previously, large collections of siRNAs were available only for traditional experimental model systems, such as human and mouse, and predominantly provided as chemically synthesized libraries.READ MORE